Keisho Chìn

11.2k total citations · 2 hit papers
187 papers, 4.6k citations indexed

About

Keisho Chìn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Keisho Chìn has authored 187 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pulmonary and Respiratory Medicine, 124 papers in Oncology and 74 papers in Surgery. Recurrent topics in Keisho Chìn's work include Gastric Cancer Management and Outcomes (121 papers), Colorectal Cancer Treatments and Studies (76 papers) and Esophageal Cancer Research and Treatment (42 papers). Keisho Chìn is often cited by papers focused on Gastric Cancer Management and Outcomes (121 papers), Colorectal Cancer Treatments and Studies (76 papers) and Esophageal Cancer Research and Treatment (42 papers). Keisho Chìn collaborates with scholars based in Japan, United States and South Korea. Keisho Chìn's co-authors include Ken Kato, Kei Muro, Atsushi Ohtsu, Narikazu Boku, Kensei Yamaguchi, Yuko Kitagawa, Shigenori Kadowaki, Mariko Ogura, Yasuo Hamamoto and Eiji Shinozaki and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Keisho Chìn

178 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

2019 751 citations Ken Kato, Keisho Chìn et al. profile →
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

2013 379 citations Atsushi Ohtsu, Keisho Chìn et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Keisho Chìn Japan	31	2.9k	2.3k	2.2k	670	560	187	4.6k
Jörg T. Hartmann Germany	31	2.7k 0.9×	2.1k 0.9×	3.4k 1.5×	762 1.1×	593 1.1×	69	5.8k
Shuichi Hironaka Japan	33	4.1k 1.4×	2.9k 1.2×	2.8k 1.2×	755 1.1×	1.1k 1.9×	149	5.8k
Joseph Chao United States	29	1.6k 0.6×	1.1k 0.5×	2.0k 0.9×	667 1.0×	465 0.8×	153	3.9k
Tomohiro Nishina Japan	35	2.2k 0.8×	1.1k 0.5×	2.7k 1.2×	665 1.0×	662 1.2×	231	4.3k
Antonio Casado Spain	33	1.5k 0.5×	1.7k 0.8×	2.5k 1.1×	679 1.0×	422 0.8×	178	5.7k
Salah‐Eddin Al‐Batran Germany	39	3.3k 1.1×	1.9k 0.8×	3.2k 1.4×	801 1.2×	1.2k 2.2×	214	5.6k
Ángel J. Lacave Spain	19	1.3k 0.4×	2.8k 1.2×	1.9k 0.8×	669 1.0×	267 0.5×	49	5.7k
Herlinde Dumez Belgium	35	2.3k 0.8×	781 0.3×	1.7k 0.8×	1.5k 2.2×	1.2k 2.2×	145	4.8k
Alicia Okines United Kingdom	27	3.2k 1.1×	1.6k 0.7×	2.1k 0.9×	548 0.8×	1.1k 2.0×	111	4.4k
Ihor Vynnychenko Ukraine	21	4.3k 1.5×	1.4k 0.6×	4.6k 2.1×	1.4k 2.1×	253 0.5×	57	7.0k

Countries citing papers authored by Keisho Chìn

Since Specialization

Citations

This map shows the geographic impact of Keisho Chìn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keisho Chìn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keisho Chìn more than expected).

Fields of papers citing papers by Keisho Chìn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keisho Chìn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keisho Chìn. The network helps show where Keisho Chìn may publish in the future.

Co-authorship network of co-authors of Keisho Chìn

This figure shows the co-authorship network connecting the top 25 collaborators of Keisho Chìn. A scholar is included among the top collaborators of Keisho Chìn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keisho Chìn. Keisho Chìn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shimozaki, Keitaro, Akira Ooki, Shota Fukuoka, et al.. (2025). Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution?. SHILAP Revista de lepidopterología. 10. 100257–100257.

Shimozaki, Keitaro, Akira Ooki, Kei Yoshino, et al.. (2025). Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice. PubMed. 7. 100128–100128. 4 indexed citations

Maron, Steven B., Keisho Chìn, Steven B. Maron, et al.. (2025). Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers. ESMO Open. 10(11). 105806–105806.

Nomura, Motoo, Keisho Chìn, Shinji Hato, et al.. (2024). Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial. Annals of Surgical Oncology. 32(1). 302–311. 1 indexed citations

Muro, Kei, Keisho Chìn, Steven B. Maron, et al.. (2024). Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.. Journal of Clinical Oncology. 42(16_suppl). 4046–4046. 2 indexed citations

Osumi, Hiroki, Izuma Nakayama, Shota Fukuoka, et al.. (2023). P-118 Clinical significance of primary tumor sites and epithelial tumor markers in patients with unresectable/recurrent gastrointestinal neuroendocrine carcinoma treated with combined chemotherapy with irinotecan and cisplatin. Annals of Oncology. 34. S56–S56. 1 indexed citations

Yamamoto, Shun, Kei Muro, Takashi Kojima, et al.. (2023). 1532P Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy. Annals of Oncology. 34. S861–S862. 4 indexed citations

Shimozaki, Keitaro, Izuma Nakayama, Daisuke Takahari, et al.. (2023). Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study. Journal of the Korean Gastric Cancer Association. 23(4). 609–609. 2 indexed citations

Takahari, Daisuke, N. Yamamoto, Akira Ooki, et al.. (2023). 1561P APC mutation (mt.), MYC, and GATA6 amplifications (amp.) were associated with worse survival in HER2-positive advanced gastric cancer patients treated with S-1/capecitabine plus oxaliplatin combined with trastuzumab (T-mab) and nivolumab (N-mab). Annals of Oncology. 34. S873–S874. 1 indexed citations

10.

Osumi, Hiroki, Teruko Ueno, Akira Ooki, et al.. (2023). Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab. International Journal of Clinical Oncology. 28(9). 1191–1199.

11.

Ura, Takashi, Shuichi Hironaka, Yasuhiro Tsubosa, et al.. (2022). Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807. Esophagus. 20(2). 272–280. 6 indexed citations

12.

Udagawa, Hibiki, Shunji Takahashi, Motohiro Hirao, et al.. (2022). Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer. Cancer Medicine. 12(2). 1269–1278. 9 indexed citations

13.

Hironaka, Shuichi, Azusa Komori, Ryunosuke Machida, et al.. (2020). The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909. Esophagus. 17(4). 417–424. 8 indexed citations

14.

Shitara, Kohei, Yoshitaka Honma, Yasushi Omuro, et al.. (2019). Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2‐positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study. Asia-Pacific Journal of Clinical Oncology. 16(1). 5–13. 13 indexed citations

15.

Yamada, Yasuhide, Wasaburo Koizumi, Kazuhiro Nishikawa, et al.. (2019). Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer. Cancer Science. 110(9). 2875–2883. 12 indexed citations

16.

Mishima, Yuji, Satoshi Matsusaka, Keisho Chìn, et al.. (2017). Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. Targeted Oncology. 12(3). 341–351. 38 indexed citations

17.

Tanigawa, Nobuhiko, Hiroki Yamaue, Shigekazu Ohyama, et al.. (2015). Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). Gastric Cancer. 19(2). 350–360. 16 indexed citations

18.

Yamaguchi, Kensei, Akira Sawaki, Toshihiko Doi, et al.. (2012). Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 16(2). 175–182. 20 indexed citations

19.

Nishimori, Hisakazu, Shunji Takahashi, Katsuyuki Kiura, et al.. (2010). Cancer of unknown primary site: a review of 28 cases and the efficacy of cisplatin/docetaxel therapy at a single institute in Japan.. PubMed. 64(5). 285–91. 5 indexed citations

20.

Seto, Yasuyuki, Kazuhiko Yamada, Takashi Fukuda, et al.. (2007). Esophageal bypass using a gastric tube and a cardiostomy for malignant esophagorespiratory fistula. The American Journal of Surgery. 193(6). 792–793. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact